Second Quarter 2016 Financial Results/Corporate Update

August 4th, 2016



Forward-looking statement

BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm




APeX-1: Phase 2 placebo-controlled trial of BCX7353 in HAE patients

Design

- Part 1: proof of concept
 - 350 mg QD BCX7353 vs placebo
 - Interim analysis at n = 24
 - Option to add up to 12 subjects for total n = 36
 - Powered at 90% (α=0.05) to detect a reduction in number of HAE attacks of ≥ 70% on BCX7353
- Part 2: dose ranging
 - 250 mg QD and 125 mg QD BCX7353 and placebo
 - n = 14
 - 6:6:2 randomization


Endpoints

- Number of HAE attacks by treatment group will be analyzed as weekly attack rate, number of attacks, proportion of subjects with no attacks, number of attack-free days
- Additional endpoints include full safety assessments, QOL, PK/PD



Avoralstat PK profiles after dosing tablet formulations, compared to soft gel capsule formulation

Plasma concentration time profile after dosing tablet formulations




BIOCRYST PHARMACEUTICALS. INC.

4


Avoralstat PK profiles after dosing suspension formulations, compared to soft gel capsule formulation

Plasma concentration time profile after dosing suspension formulations



BIOCRYST PHARMACEUTICALS, INC.

PK profile of BCX7353 dosed once daily in healthy subjects





First-in-human phase 1 clinical study of broad-spectrum antiviral nucleoside analog BCX4430, administered by intramuscular (i.m.) injection

SAD Cohort	Dose, mg/kg	Number of Subjects
1	0.3	6 active, 2 placebo
2	0.75	6 active, 2 placebo
3	1.8	6 active, 2 placebo
4	4	6 active, 2 placebo
5	7	6 active, 2 placebo
6	10	6 active, 2 placebo
Lidocaine evaluation	4	14 active

MAD Cohort	Dose, mg/kg QD for 7 days	Number of Subjects
1	2.5	7 active, 2 placebo
2	5	8 active, 2 placebo
3	10	8 active, 2 placebo

- Study BCX4430-101 evaluated the safety, tolerability, and pharmacokinetics of 1 dose and 7 days of daily dosing by i.m. injection in 91 healthy volunteers
- All planned cohorts were completed
- Effect of adding lidocaine (local anesthetic) to i.m. injections was also evaluated



BCX4430 administered by i.m. injection was generally safe and well tolerated over the range of doses and durations tested

Single doses of 0.3 mg/kg through 10 mg/kg


- 50 subjects received single doses of BCX4430 (12 subjects received placebo)
- No serious or severe adverse events occurred
- The most frequently reported AE across all cohorts was injection site pain: 23 subjects (46%)
- No clinically significant laboratory abnormalities occurred at any dose
- Co-administration of lidocaine with BCX4430 was found to ameliorate injection site pain, without altering the plasma PK profile of BCX4430

Once daily doses of 2.5 mg/kg through 10 mg/kg for 7 days

- 23 subjects received daily doses of BCX4430 with lidocaine (6 subjects received placebo)
- All subjects except 1 completed planned dosing through 7 days (one subject developed gastroenteritis unrelated to study drug)
- No serious or severe adverse events occurred
- The most frequently reported AE across all cohorts was injection site pain: 5 subjects (22%)
- No clinically significant laboratory abnormalities occurred at any dose
- With co-administration of lidocaine, the injections were well tolerated



Plasma concentration-time profile of BCX4430 on the first and last day of dosing by daily intramuscular injection



9

Phase 1 study of BCX4430 administered via IM injection in healthy volunteers: conclusions

- The study achieved all of its objectives
- BCX4430 was generally safe and well tolerated at doses up to 10 mg/kg once daily for 7 days
- Exposure was dose-proportional
- These results support the continued development of BCX4430 as a parenterally administered broad-spectrum antiviral drug for the treatment of serious emerging viral infections



Second quarter operating results

(in thousands, except per share amounts)	(Q2 2016	C	2 2015	Change Q2 2016 vs Q2 2015
Revenues:					
Royalty revenue	\$	629	\$	132	377%
Collaborative and other R&D		4,158		25,710	(84%)
Total revenues		4,787		25,842	(81%)
Expenses:					
Research and development		14,166		16,524	(14%)
General and administrative		2,724		3,534	(23%)
Royalty		27		442	(94%)
Total expenses		16,917		20,500	(17%)
(Loss) income from operations		(12,130)		5,342	(327%)
Interest and other income, net		147		116	27%
Interest expense		(1,421)		(1,306)	9%
(Loss) gain on foreign currency hedge		(2 <i>,</i> 877)		749	(484%)
Net (loss) gain	\$	(16,281)	\$	4,901	(432%)
Net (loss) gain per share - Basic	\$	(0.22)	\$	0.07	(414%)
Net (loss) gain per share - Diluted	\$	(0.22)	\$	0.06	(467%)
Net operating cash utilization	\$	15,446	\$	11,953	29%
Weighted avg shares outstanding - basic		73,695		72,642	
Weighted avg shares outstanding - diluted		73,695		76,760	



Six month operating results

(in thousands, except per share amounts)	1H 2016	1	LH 2015	Change 2016 vs 2015
Revenues: Product sales, net Royalty Revenue Collaborative and other R&D Total revenues	\$ 2,519 7,088 9,607		537 1,650 30,481 32,668	(100%) 53% (77%) (71%)
Expenses: Cost of products sold Research and development General and administrative Royalty	 34,745 5,936 104		15 33,644 7,595 502	(100%) 3% (22%) (79%)
Total expenses	40,785		41,756	(2%)
Loss from operations	(31,178)		(9,088)	243%
Interest and other income, net Interest expense (Loss) gain on foreign currency hedge	586 (2,891) (5,630)		233 (2,621) 1,213	152% 10% (564%)
Net loss	\$ (39,113)	\$	(10,263)	281%
Net loss per share - Basic & Diluted	\$ (0.53)	\$	(0.14)	279%
Net operating cash utilization	\$ 37,891	\$	15,802	140%
Weighted average shares outstanding	73,648		72,492	



Cash & investments at December 31, 2015	\$100.9		
Operating cash utilization through June 30, 2016	(\$37.9)		
Cash & investments at June 30, 2016	\$64.3		
2016 Guidance			
Operating cash utilization	\$55 — 75		
Operating expenses [#]	\$78 — 98		
Cash runway	Mid-2017		



Excludes equity-based compensation.